Search

Your search keyword '"Gouttefangeas, Cécile"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Gouttefangeas, Cécile" Remove constraint Author: "Gouttefangeas, Cécile" Database Unpaywall Remove constraint Database: Unpaywall
136 results on '"Gouttefangeas, Cécile"'

Search Results

2. 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

3. CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

12. Supplementary Table 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

13. Supplementary Table 3 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

14. Supplementary Figure 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

15. Data from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

16. Data from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

17. Supplementary Figure Legends from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

18. Supplementary Table 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

19. Supplementary Table 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

20. Supplementary Figure Legends from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

21. Supplementary Table 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

22. Supplementary Table 3 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

23. Supplementary Figure 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

24. Supplementary Figure 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

25. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

26. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

27. Supplementary Methods and Materials from Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas

28. Supplementary Methods and Materials from Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas

36. CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

37. 641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study

39. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2

40. EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

41. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

44. Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells

46. Single-domain antibodies for targeting, detection andin vivoimaging of human CD4+cells

49. List of Contributors

Catalog

Books, media, physical & digital resources